The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.155.11.1570

References

  • 1. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL: Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46:984–992 Crossref, MedlineGoogle Scholar
  • 2. Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, Fyer AJ: Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry 1997; 154:766–772 LinkGoogle Scholar
  • 3. Leon AC, Shear MK, Portera L, Klerman GL: The relationship of symptomatology to impairment in patients with panic disorder. J Psychiatr Res 1993; 27:361–367 CrossrefGoogle Scholar
  • 4. Johnson J, Weissman MM, Klerman GL: Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry 1990; 47:805–808 Crossref, MedlineGoogle Scholar
  • 5. Krystal JH, Woods SW, Hill CL, Charney DS: Characteristics of panic attack subtypes: assessment of spontaneous panic, situational panic, sleep panic, and limited symptom attacks. Compr Psychiatry 1991; 32:474–480 Crossref, MedlineGoogle Scholar
  • 6. Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Ruther E: Assessing the efficacy of treatments for panic disorder and agoraphobia, I: methodological problems. Int Clin Psychopharmacol 1995; 10:83–93 Crossref, MedlineGoogle Scholar
  • 7. Shear MK, Maser JD: Standardized assessment for panic disorder research: a conference report. Arch Gen Psychiatry 1994; 51:346–354 Crossref, MedlineGoogle Scholar
  • 8. Grove G, Coplan JD, Hollander E: The neuroanatomy of 5-HT dysregulation and panic disorder. J Neuropsychiatry Clin Neurosci 1997; 9:198–207 Crossref, MedlineGoogle Scholar
  • 9. Coplan JD, Papp LA, Pine D, Martinez J, Cooper T, Rosenblum LA, Klein DF, Gorman JM: Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 1997; 54:643–648 Crossref, MedlineGoogle Scholar
  • 10. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170:549–553 Crossref, MedlineGoogle Scholar
  • 11. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167:374–379 Crossref, MedlineGoogle Scholar
  • 12. Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1986 Google Scholar
  • 13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217–222 Google Scholar
  • 14. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA: Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997; 154:1571–1575 LinkGoogle Scholar
  • 15. Riskind JH, Beck AT, Brown G, Steer RA: Taking the measure of anxiety and depression: validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987; 175:474–479 Crossref, MedlineGoogle Scholar
  • 16. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62 Crossref, MedlineGoogle Scholar
  • 17. Sheehan DV: The Anxiety Disease. New York, Charles Scribner & Sons, 1983 Google Scholar
  • 18. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF: Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10:119–121 Crossref, MedlineGoogle Scholar
  • 19. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF: An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329–332 Crossref, MedlineGoogle Scholar
  • 20. Margraf J, Taylor B, Ehlers A, Roth WT, Agras WS: Panic attacks in the natural environment. J Nerv Ment Dis 1987; 175:558–565 Crossref, MedlineGoogle Scholar
  • 21. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush A, Kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51:559–567 Crossref, MedlineGoogle Scholar
  • 22. Fluoxetine Bulimia Nervosa Collaborative Study Group: Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992; 49:139–147 Crossref, MedlineGoogle Scholar
  • 23. Rosenbaum JF, Pollack MH, Pollock RA: Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry 1996; 57(suppl 10):44–50 Google Scholar
  • 24. Judge R, Burnham DB, Steiner MX, Gergel IP, Oakes R, Bailer DC, Wheadon DE: Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study (poster 85), in Proceedings of the Xth World Congress of Psychiatry, Madrid. New York, World Psychiatric Association, 1996, p 252 Google Scholar
  • 25. Giesecke ME: Overcoming hypersensitivity to fluoxetine in a patient with panic disorder (letter). Am J Psychiatry 1990; 147:532–533 MedlineGoogle Scholar